Obesity Drugs Fueling Class Divide: Study

Analysis of private weight loss injection prescriptions indicates a significant divide in access, with women and the middle classes leading uptake. Glucagon-like peptide-1 receptor agonists (GLP-1s), which mimic natural hormones to promote fullness, are largely prescribed privately due to phased NHS rollouts. Research indicates people in the most deprived regions are about a third less likely to access these drugs compared to those in less deprived areas, despite higher obesity levels.

Furthermore, individuals in more deprived areas tend to begin treatment at higher BMIs, suggesting delayed access and increased health risks. While the NHS is prioritizing rollout for those with significant clinical need, current data implies even eligible patients face barriers. The findings underscore the need for fair public provision and continued focus on preventative measures against obesity.